130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

Chris Parker,Daniel Heinrich,Svein Inge Helle,Joe M. O’Sullivan,Sophie D. Fossa,A. Chodacki,Tomasz Demkow,John P Logue,Mihalj Seke,Anders Widmark,Dag Clement Johannessen,Sten Nilsson,Peter Hoskin,David Bottomley,Arne Solberg,N.D. James,Isabel Syndikus,S. Wedel,J. Kliment,A. Cross,C.G. O'Bryan-Tear,J. Garcia-Vargas,Oliver Sartor

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

2012

Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases : A phase III randomized trial (ALSYMPCA)

Keywords:

Randomized controlled trial
Urology
Gynecology
Prostate cancer
Castration
Medicine
Radium-223 chloride
overall survival
castration resistant
skeletal related events

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations